Health Care & Life Sciences » Pharmaceuticals | Gemphire Therapeutics Inc.

Gemphire Therapeutics Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2014
2015
2016
2017
2018
SG&A Expense
266.00
7,168.00
14,696.00
33,124.00
22,805
EBIT
266.00
-
14,696.00
33,124.00
22,805
Unusual Expense
18.00
1,206.00
200.00
-
200
Non Operating Income/Expense
1.00
7.00
4.00
5.00
22
Interest Expense
37.00
662.00
86.00
328.00
854
Pretax Income
320.00
9,029.00
14,586.00
33,415.00
23,637
Consolidated Net Income
320.00
10,076.00
14,586.00
33,415.00
23,637
Net Income
320.00
10,076.00
14,586.00
33,415.00
23,637
Net Income After Extraordinaries
320.00
10,076.00
14,586.00
33,415.00
23,637
Net Income Available to Common
320.00
13,044.00
14,952.00
33,415.00
23,637
EPS (Basic)
0.07
4.54
2.57
3.23
1.71
Basic Shares Outstanding
4,746.60
2,875.10
5,809.40
10,349.10
13,805.60
EPS (Diluted)
0.07
4.54
2.57
3.23
1.71
Diluted Shares Outstanding
4,746.60
2,875.10
5,809.40
10,349.10
13,805.60
EBITDA
266.00
7,168.00
14,696.00
33,124.00
-
Non-Operating Interest Income
-
-
-
42.00
200
Other After Tax Income (Expense)
-
1,047.00
-
-
-
Preferred Dividends
-
2,968.00
366.00
-
-

About Gemphire Therapeutics

View Profile
Address
17199 North Laurel Park Drive
Livonia Michigan 48152
United States
Employees -
Website http://www.gemphire.com
Updated 07/08/2019
Gemphire Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It engages in the provision of treatment options for cardiometabolic diseases including dyslipidemia and NASH. It offers a small molecule formulated as a tablet product under the Gemcabene brand.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.